Cyclopharm
Cyclopharm is a global radiopharmaceutical company focused on lung imaging solutions. Their flagship product, Technegas, is used for pulmonary embolism diagnosis and other lung conditions. The company aims to advance nuclear pulmonology imaging through innovation and a commitment to superior patient care.
Short position
Cyclopharm (ASX:CYC) has 0.00% of its shares on issue reported as short positions as of 28 Sept 2026, or about 343 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.19% in August 2025. CYC is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Cyclopharm (CYC) short interest history
CYC Short Interest History
- 30-day change
- +0.00pp
- 90-day change
- -0.00pp
- 1-year change
- -0.19pp
- All-time high
- 0.19% (August 2025)
- All-time low
- 0.00% (January 2024)
Is CYC heavily shorted?
Not especially: 0.00% short interest is modest by ASX standards, ranking #706 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has CYC's short interest changed recently?
Over the past 30 days Cyclopharm's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.00% of shares on issue.
What is the highest CYC's short interest has been?
Since 2021, Cyclopharm's short interest peaked at 0.19% in August 2025 and bottomed at 0.00% in January 2024.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2021. See our methodology.